AstraZeneca buys Novexel for $430mm up front
AstraZeneca will pay $350mm in cash to acquire privately held Novexel (antibiotics). It will also transfer to shareholders an amount equal to Novexel's cash balance when the deal closes (about $80mm), and could pay up to an additional $75mm in development-based earn-outs.
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash for Equity
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com